TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Transfusion Technology Products - LOVO instrument – med device CE marked

No classification published
Location not published
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Newcastle Upon Tyne Hospitals NHS Foundation Trust: "Transfusion Technology Products - LOVO instrument – med device CE marked". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe Newcastle Upon Tyne Hospitals NHS Foundation TrustScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The Newcastle Upon Tyne Hospitals NHS Foundation Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3Bids / Report
0% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 14 active published awards; 1 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published7 Mar 2025, 11:51 GMT
Last source update7 Mar 2025, 11:51 GMT
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-04ea6f
What is being bought
Advanced Therapies service for 2x LOVO systems. Direct Award Section 41, Schedule 5 - The justification is an absence of competition and technical reasons. CRCR240163
What changed
From the official release history
  1. Status changed to complete
    7 Mar 2025, 11:51 GMT
  2. Official notice release published
    7 Mar 2025, 11:51 GMT
  3. Buyer information updated
    7 Mar 2025, 11:51 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    7 Mar 2025, 11:51 GMT
  2. Award pending
    Not published · £188,000
Commercial outcome and competition
Awards
Transfusion Technology Products - LOVO instrument – med device CE marked
£188,000 · Not published · pending
ContractsNo contract published
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Contracting authority GB-PPON-PDCY-5582-YRHQ
View buyer profile
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    buyer

    GB-PPON: PDCY-5582-YRHQ
    Regent Point, NEWCASTLE UPON TYNE, UKC22, NE7 7DN, GB
Award and contract changes
Documents (1)
Official links; attachments are not copied
  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationale• The LOVO MED is the only commercially available device with the correct level of CE Marking and the capability to handle all the techniques and processes our department requires. Alternatives on the market, would require the purchase of two different devices to cover the array of processes. • The LOVO system is tailored for larger volume applications, while the Cue system is optimized for small-volume processes. While there are only one or two alternative manufacturers in the field (or world) Fresenius Kabi’s LOVO and Cue machines are specialised in the volumes they treat. • The choice of LOVO and Cue by CGT specialists has been based on Fresenius Kabi’s systems due to the demand on specific criteria, such as volume capacity, automation level, and integration capabilities. • Fresenius Kabi’s Cell and Gene therapy is unique in that it requires advanced biological, genetic, and engineering expertise. It is not a standard piece of equipment that sees many vendors. It involves complex processes such as gene editing, stem cell manipulation, and immune cell reprogramming, which demand specialized equipment and regulatory compliance. • Strict regulations from agencies like the FDA (U.S.), EMA (Europe), and MHRA (UK) govern CGT manufacturing, requiring companies to meet rigorous compliance standards. The regulatory involvement does put off many other manufacturers wishing to develop in this field due to such high focused compliance standards. • The market for CGT is still emerging, with fewer patients receiving these therapies compared to traditional drug treatments. As CGT adoption grows, demand for automated, closed-system collection and processing equipment will maybe increase. This could lead to more competition and innovation, but for now the choice is extremely limited and we are currently the devices of choice in this field.